Thrilled to share our latest research out today in nature: “Microbial metabolite drives ageing-related clonal hematopoiesis via ALPK1” nature.com/articles/s4158…

Excited to share our paper out today in Cell Press discovering RNA mis-splicing derived neoantigens & their cognate T cell receptors (TCRs) as well as characterization of endogenous neoantigen T cells in leukemia patients. authors.elsevier.com/sd/article/S00…

🚨 Our paper is out today in Nature! 🎉🎉🎉 So excited - our paper on the neuronal influence in pancreatic cancer is out in NATURE. You can read here 👇👇👇 (nature.com/articles/s4158…)

Just published: InFocus by #AACR25 NextGen Star speaker Elvin Wagenblast concurrent with his talk: Next-Generation Strategies in B-ALL: Combining Targeted Agents and Immunotherapy brnw.ch/21wSfN1

Check out our new 'In Focus' article on overcoming B-cell acute lymphoblastic leukemia resistance by combining targeted and immune therapies! Blood Cancer Discovery Big shoutout to Miguel Quijada Álamo and Grace for their fantastic work. brnw.ch/21wSfN1

Excited to see BoneMarrowMap out in press! Please check out the R package (now capable of classifying 100,000 hematopoietic cells in 10 minutes) and consider giving the paper a read for some insights into how differentiation goes wrong in AML!

Spring 2009 I started my lab and accepted two CSHL School of Biological Sciences rotation students. Here they are, reunited at #AACR25: University of Hawaii Cancer Center clinician-scientist Elizabeth Nakasone, and The Tisch Cancer Institute assistant professor and @AACR NextGen Star Elvin Wagenblast - Made my day!

Delighted to share our study out in Cell Stem Cell today from the dream team Elli Papaemmanuil, PhD Iannis Aifantis AK Eisfeld Dan Landau! We profiled IDH-mutated AML patients to define how IDH and co-mutations shape the disease at baseline and responses to IDH-inhibitors. 🧵👇

🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in Nature Genetics 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇

WE ARE HIRING: Postdoc Positions! Join us at UPenn in vibrant Philly, cutting-edge science, great city, amazing team. Please share and let's get in touch!

Be part of the Wagenblast Lab! We are hiring a Lab Manager for leukemia & blood stem cell research at Icahn School of Medicine at Mount Sinai in NYC, starting July 2025. See ad to apply!

A switch between blood cancers🩸 Study found “multipotent” cancer cells can switch cell lineages, leading to a higher risk of drug resistance and worse outcomes. A discovery led by Dr. John Dick University Health Network Princess Margaret Cancer Centre & Dr. Charles Mullighan St. Jude Research uhnresearch.ca/news/investiga…

Support Shayan as he runs the Chicago Marathon 🏃‍♂️ this fall with the American Cancer Society, raising funds to advance cancer research! Every contribution helps make a difference - join us in cheering him on: gofund.me/4e1b986e

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies: brnw.ch/21wU2WY Elvin Wagenblast

Proud to share Jose M. Adrover’s (new PI The Francis Crick Institute) paper: As a postdoc (Cold Spring Harbor Laboratory/Johns Hopkins Medicine), he found #NETs in necrotic tumors—I shrugged. But he looked closer: NETs block tumor vessel perfusion, causing necrosis, hypoxia, EMT & #Metastasis. nature.com/articles/s4158… @JHU_BDP nature

ICYMI: Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies brnw.ch/21wUoBP Elvin Wagenblast

On Friday, August 8th, JOIN US to CELEBRATE a new generation of scientists @icahnmountsinai's #SURP4US Poster Session in the Guggenheim Pavilion. Learn More about @uofpenn's Jiamin Chen, mentored by Dr. Elvin Wagenblast Elvin Wagenblast, when she presents.

The NYC leukemia working group is back for a new season! Michael Kharas MSK Ross Levine Kira Gritsman Iannis Aifantis Kentsis Research Group Elvin Wagenblast Franco Izzo Kousteni Lab Sergei Doulatov